Mitsubishi Chemical Group has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key chemical businesses. The Japanese chemical company said ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $217 ...

Around 2% of cases of ALS – also known as motor neurone ... of tofersen," adding that in the meantime Biogen will continue to provide the drug to patients via its early-access programme.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...

Nader Yaghoubi, M.D., Ph.D., PathMaker’s Co-Founder and CEO, stated, “We are pleased to announce IRB approval for the CALM study, which allows us to commence enrollments shortly. Given the mechanisms ...

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.